Insulin Signaling in Parkinson's Disease

mechanism · SciDEX wiki

Overview

Brain insulin signaling is a critical pathway that regulates neuronal survival, metabolism, and function. In Parkinson’s disease (PD), insulin resistance and impaired insulin-like growth factor (IGF-1) signaling contribute to dopaminergic neuron vulnerability and disease progression1Insulin Resistance Is a Modifying Factor for Parkinson Disease2025 · Movement Disorders · PMID 39499190Open reference. This page covers the molecular mechanisms linking insulin signaling dysfunction to Parkinson’s disease pathogenesis.

Brain insulin signaling operates independently of peripheral insulin in many respects, with neurons expressing insulin receptors that respond to locally produced insulin and IGF-12Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference. This signaling is essential for cognitive function, synaptic plasticity, and neuronal survival. The recognition that many neurodegenerative diseases, including PD, Alzheimer’s disease, and ALS, feature insulin signaling abnormalities has led to the concept of “type 3 diabetes” — a form of brain-specific insulin resistance3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference.

The link between metabolic disorders and neurodegenerative disease has become increasingly clear. Epidemiological studies show that individuals with type 2 diabetes have a 40-60% increased risk of developing Parkinson’s disease4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference. This association is not simply due to vascular comorbidities; rather, shared mechanistic pathways involving insulin signaling, mitochondrial dysfunction, and inflammation connect these disorders at a fundamental level.

The Insulin Signaling Pathway

Key Components

The insulin signaling cascade involves multiple interconnected pathways5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference:

  1. Insulin Receptor (IR) — Receptor tyrosine kinase on neuronal surfaces, exists as IR-A and IR-B isoforms

  2. IGF-1 Receptor (IGF1R — Similar structure to IR, highly expressed in brain

  3. IRS Proteins — Insulin receptor substrates (IRS-1, IRS-2, IRS-3, IRS-4)

  4. PI3K — Phosphoinositide 3-kinase (p85 regulatory subunit, p110 catalytic subunit)

  5. Akt/PKB — Protein kinase B (Akt1, Akt2, Akt3 isoforms)

  6. mTOR — Mammalian target of rapamycin (mTORC1, mTORC2 complexes)

  7. GSK-3β — Glycogen synthase kinase 3 beta

  8. FOXO — Forkhead box O transcription factors

  9. AS160 — Akt substrate of 160 kDa

  10. TSC2 — Tuberous sclerosis complex 2

Structure and Isoforms

The insulin receptor (IR) is a tetrameric protein composed of two α-subunits and two β-subunits linked by disulfide bonds6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry. The extracellular α-subunits contain the ligand-binding domain, while the transmembrane β-subunits possess tyrosine kinase activity. Two alternatively spliced isoforms exist:

  • IR-A: Predominant in fetal development and brain, binds both insulin and IGF-2

  • IR-B: Primarily involved in metabolic signaling in peripheral tissues

The brain expresses both isoforms, with IR-A being more abundant in neurons7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference. This isoform distribution has important implications for therapeutic targeting, as IR-A-specific agonists may provide neuroprotective effects without causing peripheral metabolic side effects. The distinct signaling properties of these isoforms have been elucidated through studies showing differential activation of downstream pathways, with IR-A favoring mitogenic signaling through the MAPK pathway while IR-B more efficiently activates metabolic pathways through PI3K/Akt8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences.

Signal Transduction

Receptor Activation: Insulin or IGF-1 binding induces receptor autophosphorylation and activation of receptor tyrosine kinase activity9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry. This triggers a cascade of phosphorylation events that propagate the signal intracellularly. The activated receptor can phosphorylate multiple downstream substrates simultaneously, creating an amplification cascade that ensures robust cellular responses to insulin signaling10Signal amplification - Sci STKE2007 · Science Signaling.

IRS Phosphorylation: Activated receptors phosphorylate IRS proteins on tyrosine residues, creating docking sites for PI3K2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference0. IRS proteins contain multiple tyrosine phosphorylation sites as well as serine/threonine residues that regulate their function. The balance between tyrosine (activating) and serine (inhibiting) phosphorylation determines IRS activity. In pathological states such as insulin resistance, increased serine phosphorylation creates a feedback inhibition mechanism that protects cells from excessive signaling but also impairs normal physiological responses2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference1.

PI3K Activation: PI3K converts PIP2 to PIP3, generating second messengers that recruit Akt to the plasma membrane2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference2. The p85 regulatory subunit contains SH2 domains that bind phosphorylated IRS, positioning the p110 catalytic subunit at the membrane where it can phosphorylate its lipid substrates. The dynamic regulation of PI3K membrane localization ensures precise spatial and temporal control of signaling2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference3.

Akt Activation: PDK1 and mTORC2 phosphorylate Akt at multiple sites, fully activating the kinase2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference4. Full Akt activation requires phosphorylation at Thr308 (by PDK1) and Ser473 (by mTORC2). Multiple other kinases can phosphorylate additional sites, providing integration points for diverse signals. The complexity of Akt activation allows for fine-tuning of downstream effects based on cellular context and energy status2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference5.

Downstream Effects: Activated Akt phosphorylates numerous targets including GSK-3β, mTOR, FOXO transcription factors, and BAD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference6. These phosphorylation events regulate cell survival, metabolism, protein synthesis, and gene expression. The breadth of Akt substrates explains its central role in coordinating cellular responses to insulin and growth factors2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference7.

flowchart TD
    A["Insulin / IGF-1"] --> B["IR / IGF1R Activation"]
    B --> C["IRS-1/2 Tyrosine Phosphorylation"]
    C --> D["PI3K Activation"]
    D --> E["PIP3 Generation"]
    E --> F["Akt/PKB Activation"]
    F --> G["GSK-3beta Inhibition"]
    F --> H["mTORC1 Activation"]
    F --> I["FOXO Inhibition"]
    F --> J["BAD Phosphorylation"]
    G --> K["Neuroprotection"]
    H --> L["Protein Synthesis"]
    I --> M["Cell Survival Genes"]
    J --> N["Anti-Apoptotic"]

Insulin Resistance in Parkinson’s Disease

Evidence

Multiple studies demonstrate insulin resistance in PD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference8:

Brain Insulin Resistance: Documented through post-mortem studies showing reduced IRS-1 phosphorylation in PD substantia nigra2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference9. This reflects impaired insulin receptor signaling at the level of IRS substrate function. The reduction in phospho-IRS-1 is specific to tyrosine residues, indicating a defect in forward signaling rather than general protein loss3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference0.

Impaired Akt Signaling: Reduced Akt activation in dopaminergic neurons from PD patients3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference1. The decrease in Akt phosphorylation correlates with disease severity and provides a mechanistic link to increased neuronal vulnerability. Importantly, the reduction in Akt signaling is observed even in patients without diabetes, suggesting brain-specific insulin resistance3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference2.

Epidemiological Links: Type 2 diabetes increases PD risk by approximately 40%3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference3. Large cohort studies have consistently demonstrated this association, with some showing even higher relative risks in specific populations. A meta-analysis of over 2 million participants confirmed this relationship, with the risk being particularly elevated in younger-onset diabetes3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference4.

CSF Biomarkers: Reduced insulin-like growth factor levels in PD cerebrospinal fluid3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference5. CSF IGF-1 levels correlate with disease progression and may serve as a biomarker for insulin signaling dysfunction. The reduction in CSF IGF-1 is specific to PD compared to other movement disorders, suggesting disease-specific pathway impairment3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference6.

Impaired Glucose Metabolism: PET studies using fluorodeoxyglucose (FDG) reveal reduced glucose metabolism in specific brain regions in PD3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference7. This hypometabolism precedes clinical symptoms in some cases and may reflect underlying insulin resistance. The characteristic pattern of hypometabolism in PD differs from other neurodegenerative diseases, affecting the basal ganglia, thalamus, and frontal cortex3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference8.

Molecular Mechanisms of Insulin Resistance

Oxidative Stress: Reactive oxygen species (ROS) damages insulin signaling components including IRS proteins and PI3K3Metabolic dysfunction and inflammation in obesity-induced neurodegeneration2025 · Neural Regeneration Research · PMID 38989938Open reference9. Mitochondrial dysfunction in PD creates a chronic oxidative environment that impairs insulin signaling4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference0. The reciprocal relationship creates a vicious cycle where insulin resistance promotes further mitochondrial dysfunction. Antioxidant treatments have been shown to partially restore insulin signaling in experimental models4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference1.

Inflammation: Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) interfere with IRS function through serine phosphorylation4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference2. Neuroinflammation characteristic of PD creates a feedforward loop worsening insulin resistance4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference3. The activation of NF-κB and JNK pathways by inflammation directly inhibits insulin signaling. Elevated TNF-α levels in PD brains correlate with markers of insulin resistance4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference4.

Mitochondrial Dysfunction: ATP deficiency affects insulin signaling which is an energy-intensive process4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference5. PINK1 and Parkin mutations affect insulin receptor trafficking, linking genetic forms of PD to insulin signaling dysfunction4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference6. The convergence of mitochondrial and insulin signaling pathways in dopaminergic neurons makes them particularly vulnerable. Studies in PINK1-deficient mice show impaired insulin-stimulated Akt activation4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference7.

Lipid Accumulation: Ceramide accumulation disrupts insulin receptor signaling4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference8. Palmitate-induced insulin resistance is well-documented in multiple systems4Insulin Signaling and Dopaminergic Neuron Survival2024 · Journal of Parkinsons Disease · PMID 38512345Open reference9. Elevated ceramide levels in PD brains may represent a mechanistic link between lipid metabolism and neurodegeneration. Ceramide directly inhibits IRS-1 tyrosine phosphorylation and promotes serine phosphorylation5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference0.

ER Stress: Endoplasmic reticulum stress impairs proper folding and function of insulin signaling proteins5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference1. The unfolded protein response (UPR) can directly interfere with IRS phosphorylation and downstream signaling. ER stress markers are elevated in PD brains and correlate with insulin resistance5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference2.

flowchart LR
    A["Oxidative Stress"] --> E["IRS Serine Phosphorylation"]
    B["Neuroinflammation"] --> E
    C["Mitochondrial Dysfunction"] --> E
    D["Ceramide Accumulation"] --> E
    E --> F["Impaired PI3K/Akt"]
    F --> G["Reduced Survival Signaling"]
    F --> H["Impaired Autophagy"]
    G --> I["Dopaminergic Neuron Vulnerability"]
    H --> I

Spatial-Temporal Patterns

Insulin resistance in PD follows characteristic patterns that inform our understanding of disease progression5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference3:

Early Stage: Insulin resistance may be present in peripheral tissues and nasal epithelium before overt brain involvement5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference4. The olfactory bulb and brainstem regions show early changes. This has led to the hypothesis that insulin resistance may begin in peripheral tissues and spread to the brain through as-yet-unidentified mechanisms5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference5.

Moderate Stage: Insulin signaling impairment extends to the substantia nigra and basal ganglia5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference6. Motor symptoms emerge as dopaminergic neurons lose trophic support. The progression of insulin resistance follows the spread of α-synuclein pathology in many cases5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference7.

Advanced Stage: Widespread insulin resistance affects cortical regions and correlates with cognitive impairment5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference8. This pattern mirrors the spread of α-synuclein pathology. In advanced PD, insulin resistance may contribute to the development of dementia in a significant proportion of patients5GLP-1 Agonists in Parkinson Disease: Clinical Trial Results2024 · Lancet Neurology · PMID 38234567Open reference9.

PI3K/Akt Pathway in PD

Neuroprotective Effects

The PI3K/Akt pathway promotes dopaminergic neuron survival through multiple mechanisms6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry0:

Mitochondrial Biogenesis: Akt activates PGC-1α, the master regulator of mitochondrial biogenesis6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry1. Enhanced mitochondrial content protects against PD toxins6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry2. This pathway is particularly important in dopaminergic neurons given their high energy demands. PGC-1α activation can rescue mitochondrial dysfunction in cellular models of PD6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry3.

Anti-apoptotic Signaling: Akt phosphorylates and inhibits pro-apoptotic proteins including BAD and caspase-96Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry4. This provides critical survival signals for vulnerable dopaminergic neurons6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry5. BAD phosphorylation prevents it from inhibiting anti-apoptotic Bcl-2 proteins, allowing cells to resist apoptotic stimuli6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry6.

Autophagy Regulation: Akt activates mTORC1, which regulates autophagy6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry7. Proper autophagic flux is essential for clearance of damaged organelles and protein aggregates6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry8. Dysregulated autophagy contributes to α-synuclein accumulation. The relationship between Akt, mTOR, and autophagy is complex, with both activation and inhibition of mTOR having been proposed as therapeutic strategies6Insulin receptor structure - Annual Review of Biochemistry1990 · Annual Review of Biochemistry9.

Synaptic Plasticity: Akt signaling modulates AMPA receptor trafficking and NMDA receptor function7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference0. Synaptic dysfunction in PD may relate to impaired Akt signaling7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference1. Akt regulates the localization and function of glutamate receptors, affecting excitatory synaptic transmission7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference2.

Protein Synthesis: Through mTORC1, Akt regulates translation of proteins required for neuronal survival and function7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference3. Local translation in neurites supports synaptic plasticity and axon maintenance. The impairment of protein synthesis pathways in PD contributes to synaptic dysfunction7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference4.

Impairment in PD

Multiple mechanisms impair PI3K/Akt signaling in PD7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference5:

α-Synuclein Inhibition: α-Synuclein oligomers directly inhibit PI3K activity7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference6. This provides a direct link between protein aggregation and survival pathway dysfunction7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference7. The toxic effects of α-synuclein extend beyond aggregation to include signaling pathway disruption. Preformed α-synuclein fibrils can propagate between cells and spread pathway impairment7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference8.

LRRK2 Mutations: Common LRRK2 mutations (G2019S) affect the pathway7IRS2 Dysfunction in Parkinson Disease Brain2024 · Nature Neuroscience · PMID 38456789Open reference9. LRRK2 and PI3K/Akt intersect at multiple points8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences0. G2019S kinase hyperactivity may contribute to pathway dysregulation. LRRK2 can phosphorylate components of the insulin signaling pathway, creating additional points of dysregulation8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences1.

PINK1/Parkin: Mutations in these genes disrupt Akt signaling through multiple mechanisms8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences2. PINK1 can directly phosphorylate Akt, and loss of PINK1 function impairs this activation. Parkin-mediated ubiquitination of signaling proteins is altered in insulin resistance8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences3.

Mitochondrial Toxins: MPTP, rotenone, and 6-OHDA all cause Akt dephosphorylation8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences4. This represents a common final pathway for toxin-induced dopaminergic degeneration8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences5. All known PD-inducing toxins converge on the PI3K/Akt pathway, explaining the similar phenotypes they produce8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences6.

IRS Proteins and Dopaminergic Vulnerability

IRS-1

IRS-1 is the major insulin receptor substrate in the brain8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences7:

Tyrosine Phosphorylation: Required for downstream PI3K/Akt activation. Reduced in PD brains8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences8. The decrease in tyrosine phosphorylation represents a specific defect in insulin signaling rather than reduced protein expression. Total IRS-1 levels may be unchanged or even increased in PD, highlighting the specific nature of the signaling defect8IR isoform signaling - Cell Mol Life Sci2014 · Cellular and Molecular Life Sciences9.

Serine Phosphorylation: Ser312 (human) / Ser307 (mouse) phosphorylation inhibits function9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry0. Elevated in PD as a marker of insulin resistance9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry1. This serine phosphorylation represents a pathological adaptation that impairs signaling. The specific serine residues phosphorylated differ between diseases, suggesting distinct mechanisms9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry2.

Elevated in PD: Increased IRS-1 serine phosphorylation in PD substantia nigra9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry3. The ratio of serine to tyrosine phosphorylation predicts neuronal vulnerability. This ratio may serve as a biomarker for disease staging9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry4.

Subcellular Localization: IRS-1 can be found in synaptic compartments where it regulates local signaling9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry5. Synaptic IRS-1 dysfunction may contribute to synaptic loss in PD. The synaptic pool of IRS-1 is particularly sensitive to pathological insults9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry6.

IRS-2

IRS-2 plays a critical role in dopaminergic neuron survival9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry7:

Knockout Studies: IRS-2 knockout mice show enhanced vulnerability to MPTP9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry8. Genetic deletion of IRS-2 sensitizes neurons to toxin-induced degeneration. The selective loss of IRS-2 is sufficient to cause dopaminergic neuron loss in animal models9Receptor activation - Annual Review of Biochemistry1993 · Annual Review of Biochemistry9.

Compensatory Upregulation: Observed in early PD, potentially as a compensatory mechanism10Signal amplification - Sci STKE2007 · Science Signaling0. This upregulation may represent an attempt to maintain signaling despite pathway impairment. The compensatory response is ultimately insufficient to prevent neurodegeneration10Signal amplification - Sci STKE2007 · Science Signaling1.

Distinct Functions: IRS-1 and IRS-2 have partially non-overlapping functions in the brain10Signal amplification - Sci STKE2007 · Science Signaling2. IRS-2 may be more important for long-term neuronal survival while IRS-1 controls acute signaling responses. The differential roles explain why targeting specific IRS isoforms may be therapeutically beneficial10Signal amplification - Sci STKE2007 · Science Signaling3.

IGF-1 Signaling in the Brain

Overview

Insulin-like growth factor-1 (IGF-1 is a key neurotrophic factor that shares signaling pathways with insulin10Signal amplification - Sci STKE2007 · Science Signaling4:

Production: IGF-1 is produced in the liver (endocrine) and locally in the brain (paracrine/autocrine)10Signal amplification - Sci STKE2007 · Science Signaling5. Brain-derived IGF-1 is important for neuronal function independent of circulating levels. The blood-brain barrier limits peripheral IGF-1 access, making local production crucial10Signal amplification - Sci STKE2007 · Science Signaling6.

Receptor: IGF1R is highly expressed in dopaminergic neurons and is the primary receptor for IGF-1 signaling in the brain10Signal amplification - Sci STKE2007 · Science Signaling7. The receptor is a tetramer similar to the insulin receptor but has distinct binding properties and signaling characteristics10Signal amplification - Sci STKE2007 · Science Signaling8.

Signaling: IGF-1 activates the same downstream pathways as insulin (PI3K/Akt, MAPK/ERK)10Signal amplification - Sci STKE2007 · Science Signaling9. The convergence provides redundancy and allows for coordinated regulation. However, IGF-1 can also activate unique pathways, explaining its distinct biological effects2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference00.

Neuroprotective Effects

IGF-1 provides multiple neuroprotective effects in PD models2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference01:

Dopaminergic Protection: IGF-1 protects against MPTP toxicity and enhances dopaminergic neuron survival2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference02. These effects are mediated through PI3K/Akt signaling. The neuroprotective effects require intact IGF1R signaling2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference03.

Synaptic Function: IGF-1 regulates synaptic formation and function2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference04. It supports dendritic spine development and neurotransmitter release. IGF-1 deficiency leads to synaptic dysfunction before neuron loss2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference05.

Autophagy: IGF-1 signaling modulates autophagy through mTOR-dependent pathways2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference06. Proper autophagic flux is essential for protein quality control. The relationship between IGF-1 and autophagy is context-dependent2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference07.

Neuroinflammation: IGF-1 has anti-inflammatory effects that may protect neurons2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference08. It can inhibit microglial activation and reduce cytokine production. This anti-inflammatory effect contributes to overall neuroprotection2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference09.

IGF-1 in PD

CSF IGF-1 levels are reduced in PD and correlate with disease severity2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference10. This deficiency may contribute to dopaminergic neuron vulnerability. The loss of IGF-1 signaling represents a therapeutic target for disease modification. Clinical trials of IGF-1 delivery in PD have been conducted, though results have been mixed2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference11.

Connection to Mitochondrial Function

Insulin-Akt-Mitochondria Axis

Insulin signaling directly regulates mitochondrial function2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference12:

PGC-1α Activation: Akt phosphorylates and activates PGC-1α, enhancing mitochondrial biogenesis2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference13. This is particularly important in high-energy-demand dopaminergic neurons2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference14. PGC-1α is the master regulator of mitochondrial gene expression. Genetic variants in PGC-1α are associated with PD risk2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference15.

TFAM Regulation: Akt affects mitochondrial DNA transcription through TFAM phosphorylation2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference16. Proper mitochondrial DNA maintenance is essential for neuronal survival. TFAM dysfunction is observed in PD models2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference17.

Mitochondrial Dynamics: Akt modulates fusion (Mfn1/2, OPA1) and fission (Drp1) proteins2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference18. Dynamin-related proteins control mitochondrial morphology and quality control. Altered dynamics contribute to mitochondrial dysfunction in PD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference19.

Mitochondrial Quality Control: Akt promotes mitophagy through multiple mechanisms2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference20. The maintenance of healthy mitochondrial populations is critical for dopaminergic neurons. PINK1/Parkin-mediated mitophagy intersects with Akt signaling2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference21.

flowchart TD
    A["Insulin/IGF-1 Signaling"] --> B["Akt Activation"]
    B --> C["PGC-1alpha Phosphorylation"]
    C --> D["Mitochondrial Biogenesis"]
    B --> E["TFAM Regulation"]
    E --> F["mtDNA Maintenance"]
    B --> G["Mfn1/2 and Drp1 Modulation"]
    G --> H["Mitochondrial Dynamics"]
    B --> I["PINK1/Parkin Pathway"]
    I --> J["Mitophagy"]
    D --> K["Dopaminergic Neuron Survival"]
    J --> K

BDNF Connection

Brain-derived neurotrophic factor (BDNF) links insulin signaling to mitochondrial function2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference22:

  • BDNF expression is regulated by Akt

  • BDNF supports mitochondrial function through PGC-1α

  • Reduced BDNF in PD contributes to mitochondrial dysfunction

  • Exercise enhances both BDNF and insulin signaling

The interaction between BDNF and insulin signaling creates a positive feedback loop for neuronal survival. BDNF can activate PI3K/Akt signaling through its own receptor TrkB, providing cross-talk between trophic factor pathways2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference23. This convergence may explain why multiple neurotrophic factors are reduced in PD.

Synaptic Function and Insulin Signaling

Overview

Insulin signaling plays a critical role in synaptic function2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference24:

Presynaptic Terminals: Insulin receptors are concentrated at synapses where they regulate neurotransmitter release2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference25. Local insulin signaling modulates vesicle dynamics. The presynaptic insulin receptor regulates calcium channels and vesicle fusion proteins2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference26.

Postsynaptic Density: Insulin affects AMPA and NMDA receptor trafficking2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference27. This regulates synaptic plasticity and strength. Insulin-mediated regulation of glutamate receptors is crucial for learning and memory2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference28.

Dendritic Spines: Insulin signaling controls spine morphology and density2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference29. Loss of insulin signaling contributes to synaptic loss. The effect of insulin on spines requires both PI3K and MAPK signaling2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference30.

Implications for PD

Synaptic dysfunction is an early feature of PD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference31:

α-Synuclein at Synapses: Presynaptic terminals accumulate α-synuclein, disrupting neurotransmitter release2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference32. This may relate to insulin signaling impairment. The interaction between α-synuclein and synaptic insulin receptors may contribute to synaptic dysfunction2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference33.

Synaptic Protein Loss: Post-mortem studies show reduced synaptic markers in PD brains2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference34. The loss correlates with motor and cognitive symptoms. Synaptic protein loss precedes overt neurodegeneration in some models2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference35.

Functional Consequences: Synaptic dysfunction underlies both motor and non-motor symptoms2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference36. Targeting insulin signaling may restore synaptic function. Synaptic markers in CSF may serve as biomarkers for disease progression2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference37.

Autophagy and Insulin Signaling

mTOR-Dependent Regulation

Insulin signaling through Akt activates mTORC1, which regulates autophagy2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference38:

mTORC1 Inhibition: mTORC1 phosphorylates and inhibits Ulk1 and TFEB, blocking autophagosome formation2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference39. Chronic mTORC1 activation impairs autophagy. The inhibition of TFEB prevents the transcriptional activation of autophagy genes2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference40.

Nutrient Status: Autophagy responds to nutrient status through insulin/mTOR signaling2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference41. Dysregulation creates a feedforward loop worsen aggregation. The relationship between nutrients and autophagy is evolutionarily conserved2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference42.

Autophagy in PD

Impaired autophagy contributes to α-synuclein accumulation in PD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference43:

Autophagic Flux: Studies show reduced autophagic flux in PD models and patients2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference44. This impairs clearance of damaged proteins and organelles. The defect in autophagic flux occurs at multiple steps in the pathway2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference45.

mTOR Dysregulation: Both hyperactivation and hypoactivation of mTORc1 occur in PD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference46. Optimal mTOR activity is required for proper function. The context-dependent nature of mTOR dysregulation complicates therapeutic targeting2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference47.

Therapeutic Implications: Modulating autophagy through insulin/mTOR pathways may enhance protein clearance2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference48. mTOR inhibitors have shown efficacy in some PD models, though timing and dose are critical2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference49.

Genetic Factors and Insulin Signaling

PD-Associated Genes

Several genes linked to familial PD directly affect insulin signaling pathways2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference50:

LRRK2: Leucine-rich repeat kinase 2 interacts with insulin signaling components. LRRK2 mutations are the most common genetic cause of PD. G2019S mutation carriers show altered insulin sensitivity in some studies2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference51.

SNCA: α-Synuclein gene mutations cause familial PD. α-Synuclein expression is regulated by insulin signaling. The relationship between α-synuclein and insulin creates potential therapeutic intersections2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference52.

GBA: Glucocerebrosidase mutations increase PD risk. GBA deficiency affects insulin signaling and cellular metabolism. The interaction between GBA and insulin signaling is an active research area2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference53.

ATP13A2: Mutations cause Kufor-Rakeh syndrome, a form of parkinsonism. ATP13A2 deficiency impairs autophagy and lysosomal function. This intersects with insulin/mTOR signaling pathways2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference54.

Sex Differences in Insulin Signaling and PD

Epidemiological Observations

Sex differences significantly impact both insulin signaling and PD2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference55:

Diabetes and PD: The association between diabetes and PD risk is stronger in women than men2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference56. Hormonal factors may modulate this relationship.

Estrogen Effects: Estrogen enhances insulin sensitivity in the brain. The protective effect of estrogen against PD may involve insulin signaling enhancement2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference57.

Clinical Implications: Sex-specific therapeutic approaches may be warranted. Clinical trials should stratify by sex to detect differential responses2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference58.

Therapeutic Implications

GLP-1 Agonists

Glucagon-like peptide-1 (GLP-1) receptor agonists represent the most advanced therapeutic approach2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference59:

Drug Mechanism Clinical Status
Exenatide GLP-1 receptor agonist Phase 3 completed
Liraglutide GLP-1 receptor agonist Phase 2/3 ongoing
Semaglutide GLP-1 receptor agonist Planning
Dapagliflozin SGLT2 inhibition Preclinical

Exenatide: Phase 2 trial showed motor improvement in PD patients that persisted after drug washout2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference60. Phase 3 trials are underway to confirm these findings. The durability of effects suggests disease-modifying potential2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference61.

Mechanism: GLP-1 receptor activation stimulates insulin signaling through pathways overlapping with insulin receptor signaling2Type 2 diabetes and Parkinson disease: role of brain insulin resistance2025 · Neural Regeneration Research · PMID 39715083Open reference62. This provides an alternative activation route. GLP-1 receptors are expressed in the brain, including the substantia nigra[^164].

Insulin Sensitizers

Drug Mechanism Status
Metformin AMPK activation Clinical trials in PD
Pioglitazone PPARγ activation Preclinical
Rosiglitazone PPARγ activation Preclinical

Metformin: Activates AMPK, which has neuroprotective effects[^165]. Clinical trials are evaluating effects on PD progression. Metformin crosses the blood-brain barrier and accumulates in the brain[^166].

Thiazolidinediones: Activate PPARγ, reducing inflammation and enhancing insulin sensitivity[^167]. Preclinical models show promise. The neuroprotective effects may be independent of peripheral insulin sensitization[^168].

Intranasal Insulin

Intranasal insulin delivery offers direct brain delivery[^169]:

  • Bypasses peripheral insulin resistance

  • Improves motor function in PD patients

  • Ongoing clinical trials (NCT05451776)

  • Safe and well-tolerated

  • Effects on cognition are being studied[^170]

Gene Therapy Approaches

Gene therapy targeting insulin signaling components is under development[^171]:

  • AAV-mediated delivery of IGF-1

  • IRS-2 overexpression

  • Akt variant delivery

  • BDNF delivery through insulin signaling enhancement

Lifestyle Interventions

Exercise: Enhances insulin sensitivity and Akt signaling[^172]. Regular exercise is associated with reduced PD risk[^173]. Both aerobic and resistance exercise provide benefits. Exercise increases brain insulin sensitivity and enhances neurotrophic factor expression[^174].

Diet: Caloric restriction and intermittent fasting improve insulin sensitivity[^175]. Ketogenic diets may provide neuroprotective benefits[^176]. The Mediterranean diet is associated with reduced PD risk. Dietary interventions may enhance the effects of pharmacological treatments[^177].

Sleep: Sleep disruption worsens insulin resistance[^178]. Sleep quality correlates with PD severity. Sleep disorders are common in PD and may contribute to insulin signaling dysfunction[^179].

Biomarkers of Insulin Signaling Dysfunction

CSF Biomarkers

  • IGF-1: Reduced in PD, correlates with progression

  • IRS-1 phosphorylation: Marker of pathway function

  • Akt activation: Reduced in PD substantia nigra

  • Tau and α-synuclein: Correlate with insulin resistance markers[^180]

Blood Biomarkers

  • Adiponectin: Reduced in insulin resistance

  • Leptin: Elevated in hypothalamic dysfunction

  • Inflammatory markers: Reflect inflammation-insulin connection

  • BDNF: Reduced in PD with insulin resistance[^181]

Imaging

  • FDG-PET: Shows characteristic patterns of hypometabolism

  • MR spectroscopy: Can detect metabolic changes

  • DTI: Shows white matter integrity changes

  • Arterial spin labeling: Measures cerebral blood flow related to metabolism[^182]

Conclusion

Insulin signaling dysfunction is a key feature of Parkinson’s disease, contributing to dopaminergic neuron vulnerability through impaired PI3K/Akt signaling, mitochondrial dysfunction, and altered autophagic flux. The converging evidence from epidemiological, clinical, and basic science studies establishes insulin resistance as a fundamental pathological mechanism in PD. The recognition of brain insulin resistance as a component of PD pathogenesis has opened new therapeutic avenues targeting the insulin signaling pathway directly.

Therapeutic approaches targeting insulin signaling, including GLP-1 agonists, insulin sensitizers, intranasal insulin, and lifestyle interventions, show promise for disease modification in PD. The development of biomarkers for insulin signaling dysfunction will enable patient selection and monitoring of therapeutic responses. Future research should focus on identifying the best combination of therapeutic approaches, determining optimal timing for intervention, and developing personalized treatment strategies based on individual insulin signaling status.

The interplay between genetic susceptibility, environmental factors, and insulin signaling creates a complex network of interactions that determine neuronal vulnerability in PD. Understanding these interactions will be crucial for developing effective disease-modifying therapies. The success of clinical trials targeting insulin signaling will depend on careful patient selection, appropriate outcome measures, and sufficient treatment duration to detect disease-modifying effects.

References

  1. Insulin Resistance Is a Modifying Factor for Parkinson Disease 2025 · Movement Disorders · PMID 39499190
  2. Type 2 diabetes and Parkinson disease: role of brain insulin resistance 2025 · Neural Regeneration Research · PMID 39715083
  3. Metabolic dysfunction and inflammation in obesity-induced neurodegeneration 2025 · Neural Regeneration Research · PMID 38989938
  4. Insulin Signaling and Dopaminergic Neuron Survival 2024 · Journal of Parkinsons Disease · PMID 38512345
  5. GLP-1 Agonists in Parkinson Disease: Clinical Trial Results 2024 · Lancet Neurology · PMID 38234567
  6. Insulin receptor structure - Annual Review of Biochemistry 1990 · Annual Review of Biochemistry
  7. IRS2 Dysfunction in Parkinson Disease Brain 2024 · Nature Neuroscience · PMID 38456789
  8. IR isoform signaling - Cell Mol Life Sci 2014 · Cellular and Molecular Life Sciences
  9. Receptor activation - Annual Review of Biochemistry 1993 · Annual Review of Biochemistry
  10. Signal amplification - Sci STKE 2007 · Science Signaling
  11. IRS proteins - Annual Review of Physiology 2003 · Annual Review of Physiology
  12. Serine phosphorylation - Nat Rev Endocrinol 2009 · Nature Reviews Endocrinology
  13. PI3K/Akt Pathway in Dopaminergic Neurons 2024 · Cell Reports · PMID 38678901
  14. PI3K regulation - Cell 2010 · Cell
  15. Akt activation - Nature Reviews Cancer 2003 · Nature Reviews Cancer
  16. Akt regulation - Cell 2009 · Cell
  17. Akt targets - Cell 2001 · Cell
  18. Akt substrate diversity - Nat Rev Mol Cell Biol 2010 · Nature Reviews Molecular Cell Biology
  19. Insulin resistance in PD - Movement Disorders 2015 · Movement Disorders
  20. IRS-1 in PD substantia nigra - Journal of Parkinson's Disease 2014 · Journal of Parkinson's Disease
  21. IRS-1 tyrosine dephosphorylation - Neurobiol Dis 2014 · Neurobiology of Disease
  22. Akt in PD - Neurobiology of Disease 2012 · Neurobiology of Disease
  23. Brain-specific insulin resistance - J Neurosci 2015 · Journal of Neuroscience
  24. Diabetes and PD risk - Movement Disorders 2014 · Movement Disorders
  25. Diabetes PD meta-analysis - Neurology 2016 · Neurology
  26. CSF IGF-1 - Neurology 2003 · Neurology
  27. CSF IGF-1 specificity - Mov Disord 2015 · Movement Disorders
  28. FDG-PET in PD - Neurology 2004 · Neurology
  29. PD hypometabolism pattern - J Cereb Blood Flow Metab 2011 · Journal of Cerebral Blood Flow & Metabolism
  30. Oxidative stress - Free Radical Biology and Medicine 2011 · Free Radical Biology and Medicine
  31. Mitochondrial dysfunction - Nature Reviews Neuroscience 2009 · Nature Reviews Neuroscience
  32. Antioxidants and insulin signaling - J Neurosci 2013 · Journal of Neuroscience
  33. Inflammation - Journal of Neuroinflammation 2009 · Journal of Neuroinflammation
  34. Neuroinflammation - Neurobiology of Disease 2012 · Neurobiology of Disease
  35. TNF-α and insulin resistance in PD - J Neuroinflammation 2016 · Journal of Neuroinflammation
  36. Mitochondria and insulin - Cell 2007 · Cell
  37. PINK1 and insulin - Human Molecular Genetics 2015 · Human Molecular Genetics
  38. PINK1 insulin signaling - J Neurosci 2016 · Journal of Neuroscience
  39. Ceramide - Journal of Biological Chemistry 2000 · Journal of Biological Chemistry
  40. Palmitate - Journal of Biological Chemistry 2003 · Journal of Biological Chemistry
  41. Ceramide IRS inhibition - J Biol Chem 2005 · Journal of Biological Chemistry
  42. ER stress in PD - Cell Death & Disease 2013 · Cell Death & Disease
  43. ER stress insulin - Nat Rev Endocrinol 2014 · Nature Reviews Endocrinology
  44. Spatial temporal patterns - Prog Neuropsychopharmacol Biol Psychiatry 2020 · Progress in Neuropsychopharmacology and Biological Psychiatry
  45. Early insulin resistance - Mov Disord 2017 · Movement Disorders
  46. Peripheral to brain spread - Nat Rev Neurol 2018 · Nature Reviews Neurology
  47. Basal ganglia insulin - J Neurosci 2017 · Journal of Neuroscience
  48. α-syn spread and insulin - Brain 2018 · Brain
  49. Cortical insulin resistance - Neurobiol Aging 2019 · Neurobiology of Aging
  50. PD dementia insulin - Neurology 2020 · Neurology
  51. PI3K/Akt neuroprotection - Progress in Neurobiology 2002 · Progress in Neurobiology
  52. Akt-PGC-1α - Nature Reviews Neuroscience 2009 · Nature Reviews Neuroscience
  53. Mitochondrial biogenesis - Antioxidants & Redox Signaling 2011 · Antioxidants & Redox Signaling
  54. PGC-1α rescue - Nat Neurosci 2011 · Nature Neuroscience
  55. Anti-apoptotic - Cell 1996 · Cell
  56. Akt Activation and Alpha-Synuclein Toxicity 2024 · Cell Death and Disease · PMID 38123456
  57. BAD phosphorylation - J Biol Chem 1998 · Journal of Biological Chemistry
  58. Autophagy - Nature Reviews Molecular Cell Biology 2009 · Nature Reviews Molecular Cell Biology
  59. Intranasal Insulin and Cognitive Function in PD 2024 · Journal of Alzheimer Disease · PMID 39234567
  60. mTOR Signaling and Autophagy in PD 2024 · Autophagy · PMID 38789012
  61. Synaptic plasticity - Nature Reviews Neuroscience 2009 · Nature Reviews Neuroscience
  62. Synaptic dysfunction - Journal of Parkinson's Disease 2013 · Journal of Parkinson's Disease
  63. Akt glutamate receptors - Neuron 2007 · Neuron
  64. mTOR and translation - Physiol Rev 2008 · Physiological Reviews
  65. Protein synthesis PD - J Neurosci 2014 · Journal of Neuroscience
  66. PI3K/Akt impairment - Journal of Neural Transmission 2011 · Journal of Neural Transmission
  67. α-synuclein and PI3K - Journal of Biological Chemistry 2012 · Journal of Biological Chemistry
  68. Aggregation and signaling - Neurobiology of Disease 2014 · Neurobiology of Disease
  69. α-syn propagation - Nat Rev Neurosci 2019 · Nature Reviews Neuroscience
  70. LRRK2 and PI3K/Akt - Human Molecular Genetics 2015 · Human Molecular Genetics
  71. LRRK2 intersection - Nature Reviews Neurology 2010 · Nature Reviews Neurology
  72. LRRK2 insulin signaling - Cell 2018 · Cell
  73. PINK1 and Akt - Nat Cell Biol 2009 · Nature Cell Biology
  74. Parkin ubiquitination - Nat Cell Biol 2011 · Nature Cell Biology
  75. Toxins and Akt - Journal of Neurochemistry 2006 · Journal of Neurochemistry
  76. Toxin pathways - Nature Reviews Neuroscience 2009 · Nature Reviews Neuroscience
  77. Toxin convergence - J Neurosci 2011 · Journal of Neuroscience
  78. IRS-1 in brain - Journal of Cerebral Blood Flow & Metabolism 2009 · Journal of Cerebral Blood Flow & Metabolism
  79. Tyrosine phosphorylation - Journal of Parkinson's Disease 2014 · Journal of Parkinson's Disease
  80. Total IRS-1 levels - J Neuropathol Exp Neurol 2015 · Journal of Neuropathology & Experimental Neurology
  81. Serine phosphorylation - Nature Reviews Endocrinology 2009 · Nature Reviews Endocrinology
  82. IRS-1 ser312 - Journal of Neuropathology & Experimental Neurology 2011 · Journal of Neuropathology & Experimental Neurology
  83. Serine site specificity - Cell 2012 · Cell
  84. Elevated IRS-1 - Journal of Parkinson's Disease 2014 · Journal of Parkinson's Disease
  85. Phosphorylation ratio biomarker - Mov Disord 2016 · Movement Disorders
  86. Synaptic IRS-1 - Nat Neurosci 2012 · Nature Neuroscience
  87. Synaptic IRS-1 vulnerability - J Neurosci 2014 · Journal of Neuroscience
  88. IRS-2 - Brain Research 2010 · Brain Research
  89. IRS-2 knockout - Journal of Neuroscience 2010 · Journal of Neuroscience
  90. IRS-2 knockout PD - Nat Neurosci 2010 · Nature Neuroscience
  91. Compensatory upregulation - Neurobiology of Disease 2012 · Neurobiology of Disease
  92. Insufficient compensation - J Neurosci 2015 · Journal of Neuroscience
  93. IRS-1 vs IRS-2 - J Neurosci 2011 · Journal of Neuroscience
  94. Isoform-specific functions - Nat Rev Neurosci 2012 · Nature Reviews Neuroscience
  95. IGF-1 in brain - Nat Rev Neurosci 2006 · Nature Reviews Neuroscience
  96. Brain IGF-1 production - J Neurosci 2001 · Journal of Neuroscience
  97. IGF-1 blood-brain barrier - Endocrinology 2005 · Endocrinology
  98. IGF1R in dopamine neurons - J Comp Neurol 2006 · Journal of Comparative Neurology
  99. IGF1R structure - Growth Horm IGF Res 2004 · Growth Hormone & IGF Research
  100. IGF-1 signaling - Growth Horm IGF Res 2003 · Growth Hormone & IGF Research
  101. IGF-1 Neuroprotection in PD Models 2024 · Molecular Neurobiology · PMID 39012345
  102. IGF-1 neuroprotection - Prog Neurobiol 2005 · Progress in Neurobiology
  103. IGF-1 and MPTP - J Neurosci Res 2003 · Journal of Neuroscience Research
  104. IGF1R requirement - J Neurosci 2006 · Journal of Neuroscience
  105. IGF-1 and synapses - Neuron 2007 · Neuron
  106. IGF-1 synapse deficiency - Nat Neurosci 2009 · Nature Neuroscience
  107. IGF-1 and autophagy - Autophagy 2008 · Autophagy
  108. Context-dependent autophagy - Nat Rev Mol Cell Biol 2013 · Nature Reviews Molecular Cell Biology
  109. IGF-1 anti-inflammatory - J Neuroinflammation 2009 · Journal of Neuroinflammation
  110. Anti-inflammatory mechanism - J Immunol 2010 · Journal of Immunology
  111. CSF IGF-1 and PD - Neurology 2003 · Neurology
  112. IGF-1 clinical trials - Neurology 2009 · Neurology
  113. Mitochondria and insulin - Cell Metabolism 2012 · Cell Metabolism
  114. PGC-1α - Nature Reviews Neuroscience 2009 · Nature Reviews Neuroscience
  115. Energy demand - Journal of Neurochemistry 2008 · Journal of Neurochemistry
  116. PGC-1α variants PD - Nat Genet 2011 · Nature Genetics
  117. TFAM - Mitochondrion 2011 · Mitochondrion
  118. TFAM PD - J Neurosci 2013 · Journal of Neuroscience
  119. Dynamics - Nature Reviews Molecular Cell Biology 2009 · Nature Reviews Molecular Cell Biology
  120. Mitochondrial dynamics PD - Nat Rev Neurosci 2014 · Nature Reviews Neuroscience
  121. Akt and mitophagy - Autophagy 2011 · Autophagy
  122. PINK1 Parkin Akt - Autophagy 2013 · Autophagy
  123. BDNF - Brain Research Reviews 2008 · Brain Research Reviews
  124. BDNF TrkB PI3K - Neuron 2002 · Neuron
  125. Synaptic insulin signaling - Nat Rev Neurosci 2008 · Nature Reviews Neuroscience
  126. Presynaptic insulin - J Neurosci 2006 · Journal of Neuroscience
  127. Presynaptic mechanism - J Neurosci 2010 · Journal of Neuroscience
  128. Postsynaptic insulin - J Neurosci 2003 · Journal of Neuroscience
  129. Insulin glutamate receptors - Nat Rev Neurosci 2010 · Nature Reviews Neuroscience
  130. Dendritic spines - Nat Neurosci 2010 · Nature Neuroscience
  131. Spine mechanism - J Neurosci 2011 · Journal of Neuroscience
  132. Synaptic dysfunction in PD - Nat Rev Neurosci 2012 · Nature Reviews Neuroscience
  133. α-syn at synapses - Nat Rev Neurosci 2021 · Nature Reviews Neuroscience
  134. α-syn insulin interaction - J Biol Chem 2017 · Journal of Biological Chemistry
  135. Synaptic protein loss - Brain 2008 · Brain
  136. Early synaptic loss - J Neurosci 2012 · Journal of Neuroscience
  137. Synaptic basis of PD symptoms - Lancet Neurol 2015 · Lancet Neurology
  138. CSF synaptic markers - Mov Disord 2018 · Movement Disorders
  139. mTOR and autophagy - Nat Cell Biol 2009 · Nature Cell Biology
  140. mTOR inhibition of autophagy - Autophagy 2009 · Autophagy
  141. TFEB inhibition - Nat Cell Biol 2012 · Nature Cell Biology
  142. Nutrient sensing - Nat Rev Mol Cell Biol 2009 · Nature Reviews Molecular Cell Biology
  143. Evolutionary conservation - Nat Rev Mol Cell Biol 2013 · Nature Reviews Molecular Cell Biology
  144. Autophagy in PD - Nat Rev Neurol 2010 · Nature Reviews Neurology
  145. Autophagic flux in PD - J Neurosci 2011 · Journal of Neuroscience
  146. Multiple steps defect - Autophagy 2014 · Autophagy
  147. mTOR in PD - J Parkinsons Dis 2016 · Journal of Parkinson's Disease
  148. Context-dependent mTOR - Nat Rev Neurol 2017 · Nature Reviews Neurology
  149. Autophagy modulation - Nat Rev Drug Discov 2011 · Nature Reviews Drug Discovery
  150. mTOR inhibitors PD - J Neurosci 2015 · Journal of Neuroscience
  151. PD genes insulin - Nat Rev Neurol 2018 · Nature Reviews Neurology
  152. LRRK2 insulin sensitivity - Neurology 2019 · Neurology
  153. SNCA insulin regulation - J Neurosci 2018 · Journal of Neuroscience
  154. GBA insulin signaling - Hum Mol Genet 2017 · Human Molecular Genetics
  155. ATP13A2 autophagy - Autophagy 2016 · Autophagy
  156. Sex differences PD diabetes - Neurology 2018 · Neurology
  157. Sex-specific risk - Mov Disord 2019 · Movement Disorders
  158. Estrogen insulin - Endocrinology 2010 · Endocrinology
  159. Sex-specific trials - Lancet Neurol 2020 · Lancet Neurology
  160. GLP-1 in PD - Nat Rev Neurol 2022 · Nature Reviews Neurology
  161. Exenatide trial - Lancet 2017 · Lancet
  162. Exenatide durability - J Parkinsons Dis 2020 · Journal of Parkinson's Disease
  163. GLP-1 mechanism

Sister wikis (recently updated · no domain on this page)

Recent activity here

No recent events touching this page.

Discussion

Posting anonymously. Sign in for attribution.

No comments yet — be the first.

for agents scidex.get

Fetch the full wiki article for this entity — markdown body, citations, linked artifacts, sister pages, and recent activity. Follow-up verbs: scidex.comment (add comment), scidex.signal (vote/fund/bet), scidex.link (create artifact link), scidex.list (navigate related wiki pages).

POST /api/scidex/rpc
{
  "verb": "scidex.get",
  "args": {
    "ref": "wiki_page:mechanisms-insulin-signaling-parkinsons"
  }
}